Glomerular diseases contribute significantly to the End Stage Kidney Disease burden in the United States. Although there are a number of specific therapies for glomerular diseases, and many more under development, several factors mitigate the effectiveness of these treatments. Most glomerular diseases need to be diagnosed by kidney biopsy, and the invasive nature of this procedure often causes it to be put off until the clinical signs of kidney injury are significant. This waiting period may result in accrual of chronc, irreversible damage that could have been prevented with earlier diagnosis and intervention. Furthermore, the therapies used for glomerular diseases often involve immunosuppressive drugs with their associated toxicities. Because native kidney biopsies are not done serially, these toxic therapies are monitored clinically. However, treatment efficacy could be improved if renal pathology was monitored in real time and used to titrate therapy. We therefore propose using combinations of novel urine and traditional clinical biomarkers (e.g. proteinuria) to derive composite biomarkers that accurately reflect kidney pathology. Unlike previous studies of urine biomarkers using a non-targeted total urine proteomics approach, or a candidate approach based on the literature, the individual urine biomarkers for this study will be informed by proteomic analysis of laser-captured microdissected glomeruli and tubulointerstitium collected from defined glomerular diseases and specific pathologic lesions important across a spectrum of glomerular diseases. Differentially-expressed tissue proteins will be considered candidate biomarkers. The presence of these candidate biomarkers in urine will be verified and then candidates present in the urine will be quantified. Combinations of the excreted candidate biomarkers and clinical data will be tested mathematically to determine the optimal composition of a biomarker for each type of glomerular disease or pathologic lesion. These composite biomarkers will be validated in independent urine samples collected prospectively from patients undergoing diagnostic kidney biopsy. It is expected that this work will result in a panel of composite biomarkers that can be used to non-invasively diagnose glomerular diseases and follow changes in kidney histology during therapy so as to improve management of glomerular diseases.

Public Health Relevance

This work will develop a series of urine tests that can be used to understand what is going on in the kidneys of patients with glomerular diseases. These tests will provide information that currently can only be obtained by kidney biopsy. It is expected that these tests will provide a non-invasive way to diagnose glomerular diseases, and to follow changes in the kidney during treatment of glomerular diseases. Using these urine tests, treatments can be adjusted more precisely to an individual patient's response, and will lead to improved patient outcomes.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Pathobiology of Kidney Disease Study Section (PBKD)
Program Officer
Kimmel, Paul
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Ohio State University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Parikh, Samir V; Malvar, Ana; Song, Huijuan et al. (2017) Molecular imaging of the kidney in lupus nephritis to characterize response to treatment. Transl Res 182:1-13
Birmingham, Daniel J; Merchant, Michael; Waikar, Sushrut S et al. (2017) Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise. Nephrol Dial Transplant 32:i71-i79
Gulati, G; Bennett, M R; Abulaban, K et al. (2017) Prospective validation of a novel renal activity index of lupus nephritis. Lupus 26:927-936
Indrakanti, D L; Alvarado, A; Zhang, X et al. (2017) The interleukin-6-hepcidin-hemoglobin circuit in systemic lupus erythematosus flares. Lupus 26:200-203
Almaani, Salem; Meara, Alexa; Rovin, Brad H (2017) Update on Lupus Nephritis. Clin J Am Soc Nephrol 12:825-835
Anders, Hans-Joachim; Jayne, David R W; Rovin, Brad H (2016) Hurdles to the introduction of new therapies for immune-mediated kidney diseases. Nat Rev Nephrol 12:205-16
Brunner, Hermine I; Bennett, Michael R; Abulaban, Khalid et al. (2016) Development of a Novel Renal Activity Index of Lupus Nephritis in Children and Young Adults. Arthritis Care Res (Hoboken) 68:1003-11
Anders, Hans-Joachim; Rovin, Brad (2016) A pathophysiology-based approach to the diagnosis and treatment of lupus nephritis. Kidney Int 90:493-501
Parikh, Samir V; Rovin, Brad H (2016) Current and Emerging Therapies for Lupus Nephritis. J Am Soc Nephrol 27:2929-2939
Caster, Dawn J; Hobeika, Liliane; Klein, Jon B et al. (2015) Changing the concepts of immune-mediated glomerular diseases through proteomics. Proteomics Clin Appl 9:967-71

Showing the most recent 10 out of 14 publications